Etoposide

目录号:S1225 别名: VP-16, VP-16213

Etoposide Chemical Structure

Molecular Weight(MW): 588.56

Etoposide是一种鬼臼毒素的半合成衍生物,通过抑制topoisomerase II 活性而抑制DNA合成。

规格 价格 库存 购买数量  
RMB 749.41 现货
RMB 575.72 现货
RMB 2290.17 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用该产品的6个实验数据:

  • ABT-199 synergizes strongly with lymphoma chemotherapy agents that affect MCL1 levels. Viability and CI vs Fa after 24-h exposure to etoposide alone or in combination with ABT-199 in Riva, U2932 and VavP-Bcl2/c-MYC murine tumor cells. Viability shown at 500 nM.

    Leukemia, 2015, 29: 1702–1712. Etoposide purchased from Selleck.

    Dox promotes formation of DNA DSBs in primary neurons. (A) Cortical neurons at 28–32 DIV were treated with a vehicle or with Dox (0.1 μ M) or with DNA damaging drug etoposide (5 μ M) overnight, fixed, and stained for a marker of DSBs phosphorylated histone H2A variant X, γ H2A.X (green), MAP2c (red), and with the nuclear Hoechst dye (blue), and imaged. The neuronal nucleus is enlarged on the Dox panel to illustrate the γ H2A.X puncta. Note the green nuclear staining in cells treated with Dox and etoposide. Also note the reduced dendritic arborization in neurons treated with Dox and etoposide. Scale bar is 20 μm.

    Sci Rep, 2016, 6:25705.. Etoposide purchased from Selleck.

  • Viability of U87 cells(C) assessed by the Alamar blue assay, 72 h after transfection with siRNA anti-survivin (siSURV) or with siMUT and/or cell incubation with the chemotherapeutical drugs etoposide (ETO) and Bliss interaction index (D) determined for the combined effects on cell viability of survivin silencing plus treatment with each drug. Cells were transfected, for 4 h, with (14Ser)2N5/siRNA/HL complexes and, after an additional period of 20 h, cells were incubated with 1.5 μM ETO (C) for 48 h. Results, representative of at least three independent experiments, are expressed as a percentage of the nontreated control cells. Combined treatment (dotted bar) was compared with the single drug treatment (gray bar) (**p < 0.01, ***p < 0.001) and the Bliss interaction index of each combined treatment was compared with the theoretical value expected for an additive effect (1.0) (#p < 0.05, ns, non-significant).

    Eur J Pharm Biopharm, 2016, 104:7-19.. Etoposide purchased from Selleck.

    Cellular biomarker responses in HT29 cells exposed to various cytotoxic chemotherapeutic agents in combination with the Chk1 inhibitor V158411. HT29 cells were exposed to the combination GI80 of gemcitabine (0.2 uM), camptothecin (0.44 uM), cisplatin (68 uM), oxaliplatin (131 uM), doxorubicin (1.2 uM) or etoposide (59 uM) for 18 hours followed by DMSO (-) or 400 nM V158411 (+) for a further 24 hours. Protein expression was characterized by immunoblotting.

    BMC Cancer 2014 14, 483. Etoposide purchased from Selleck.

  • (c) and (d) Effects of fractions C4 and C5 on topoisomerase II activity. Topoisomerase II activity was measured by plasmid DNA cleavage assay. DNA bands were visualized using UV light and the intensity of linear DNA band in each lane was measured using imageJ software. Lane 1: plasmid PBR322DNA. Lane 2: control, topoisomerase II + plasmid PBR322DNA. Lanes 3, 4, and 5: 40, 20, and 10 μg/mL fraction C4 + plasmid PBR322DNA, respectively. Lanes 6, 7, and 8: 40, 20, and 10 μg/mL fraction C5 + plasmid PBR322DNA, respectively. Lane 9: 100 μM etoposide + plasmid PBR322DNA. The data in different groups were expressed as the mean ± SD from 3 experiments. Statistical difference between groups was assessed by t-test using SPSS 20.0. ∗∗P < 0.01 versus the control group.

    Evid Based Complement Alternat Med, 2017, 2017:1456786. Etoposide purchased from Selleck.

    Effects of etoposide on the radiosensitivities of cholangiocarcinoma cell lines. The cell survival curves of (A) KKU-M055 and (B) KKU-M214 cells were obtained from clonogenic survival assays. The cells were treated with X-ray irradiation or etoposide (0.025 or 0.05 µg/ml) alone or pretreated with etoposide for 24 h prior to X-ray irradiation. Survival fractions were determined at day 10 following X-ray irradiation. The dose-response curves depict the mean ± standard deviation of survival fractions of three independent experiments. IR, irradiation.

    Oncol Lett, 2018, 15(3):3895-3903. Etoposide purchased from Selleck.

产品安全说明书

Topoisomerase抑制剂选择性比较

生物活性

产品描述 Etoposide是一种鬼臼毒素的半合成衍生物,通过抑制topoisomerase II 活性而抑制DNA合成。
靶点
Topo II [2]
(Cell-free assay)
体外研究

Etoposide通过与Topoisomerase II 和 DNA形成复合物而抑制DNA合成,诱导双链DNA断裂,且阻碍通过 Topoisomerase II结合修复。DNA持续断裂阻碍进入细胞有丝分裂期,进而导致细胞死亡。Etoposide主要作用于细胞周期的G2期和S期。[1] Etoposide 抑制鼠类血管肉瘤细胞系 (ISOS-1) 生长,IC50 为0.25 μg/mL。Etoposide 抑制人类白血病成淋巴细胞系CCRF-CEM的四倍体克隆,IC50为0.6 μM。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly NFy4SZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPmZ4Q6UUN3ME2wMlEz6oDLwsJihKkxNjBzIN88US=> Mom1NlU6PjB{OEK=
KellyCis83 M{DjcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLEeJVTUUN3ME2wMlE36oDLwsJihKkxNjB{IN88US=> M3LUcFI2QTZyMkiy
SK-N-AS NInEXo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTWPZRKSzVyPUCuNlTjiIoEsfMAjVAvODNizszN M3T2U|I2QTZyMkiy
SK-N-ASCis24 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\DcpBRUUN3ME2wMlU46oDLwsJihKkxNjFzIN88US=> MVqyOVk3ODJ6Mh?=
U87 MkDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorPNE02OCEQvF2= MXy0PEBp NFvVV|Bl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImge4hq[2hiY3HuJIJmKGWwaHHuZ4VlKGK7IIPpcIljcW6rbh?= MX6yOVc2ODJ5Mx?=
HCT116 M17BZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXKwMlUuOi53IN88US=> M4HQfVQ5yqCqwrC= MmnNTWM2OD1zLkezxsDDucLiMD6yNeKh|ryP NFy2THkzPTd2Nke2Ny=>
HT-29 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\acFIxNjVvMj61JO69VQ>? M37FUFQ5yqCqwrC= Mo\xTWM2OD15LkNCpOKyyqBzLkC0xsDPxE1? NWrMSXQ3OjV5NE[3OlM>
Caco2 MlfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVixWG9ROC53LUKuOUDPxE1? MVq0POKhcMLi MorxTWM2OD15LkK2xsDDucLiMT62POKh|ryP NF\zbVMzPTd2Nke2Ny=>
COLO 205 MoHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjwTFVuOC53LUKuOUDPxE1? MkHFOFjDqGkEoB?= MYPJR|UxRTFwNkJCpOKyyqByLkCyxsDPxE1? MYCyOVc1Pjd4Mx?=
SW480 MkTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDMNE42NTJwNTFOwG0> MnL3OFjDqGkEoB?= MVjJR|UxRTRwOUNCpOKyyqByLkOzxsDPxE1? MkDSNlU4PDZ5NkO=
HEK293T M2nyd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfLNU02KM7:TR?= M2C5SlQ5yqCqwrC= NXvLbGJqUUN3ME2yMlQzyqEEsdMgNE4xPcLizszN M2Pvc|I2PzR4N{[z
Hep3B  MYPGeY5kfGmxbjDBd5NigQ>? MYixNEDPxE1? NF20eos1QMLiaNMg NUK2XYM{emWmdXPld{B1cGViZX7oZY5kcW6pIHXm[oVkfCCxZjDCUXAuPg>? NVPJOlNtOjV4M{O1OlQ>
Hep3B  MYHGeY5kfGmxbjDBd5NigQ>? MknpNE4yNTFyIN88US=> NUPjcHVHOjRiaB?= NX;velRZe3WycILld5NmeyC2aHWg[ZhxemW|c3nvckBw\iCqZYDjbYRqdiCvUl7B NFjUdoUzPTZ|M{W2OC=>
HEK293 Mo\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTdwMUVCpOKyyqByLkO2xsDPxE1? MoHQNlU3ODNzMkK=
DU145 Mo\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVv0XGM6UUN3ME2yMlI5yqEEsdMgNE4xPMLizszN NFrtVWYzPTZyM{GyNi=>
HCT15 M13YN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPiTWM2OD1yLkixxsDDucLiMD6wNeKh|ryP MV6yOVYxOzF{Mh?=
T47D M4fkOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHCTWM2OD1|LkG4xsDDucLiMD6xNeKh|ryP NFHzO24zPTZyM{GyNi=>
SMMC-7721 Ml\HSpVv[3Srb36gRZN{[Xl? NXXvOohsPDBizszN MX20PEBp M3vMbGROW09? NYTNW2YxcW6mdXPld{DPu0h{QWig[o9kcSCob4LtZZRqd25? M2D4SlI2PTR2M{[x
MDA-MB-231 NUnTXZhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXlSI04OsLiaB?= MXfJR|UxRTJzLkNCpOKyyqB2LkNCpO69VQ>? NXfCR45ZOjV2OE[yNVk>
MCF-7 MnnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1m1XlczyqCq MYTJR|UxRTFyLkpCpOKyyqB{LkJCpO69VQ>? MXiyOVQ5PjJzOR?=
Jurkat NEXkT2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mon3O|LDqGh? NH3Lb5JKSzVyPUGuNuKhyrIEoEGuOeKh|ryP NUXvW4dYOjV2OE[yNVk>
HeLa MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2[0e|czyqCq NIPEboJKSzVyPUOuPeKhyrIEoEKuN:Kh|ryP M1LBXFI2PDh4MkG5
MCF7  NWrWc4dRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\hOU0yODBizszN M{HWcFch\A>? NEHXUIFqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M3vFVFI2PDd{NkG5
K562 M37uUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYe3NuKhcA>? NYq4eHU{UUN3ME2wMlI6yqEQvF2= MlvuNlUzQDJ4NUO=
K/VP.5 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzZOVBOPzMEoHi= NHyxdYNKSzVyPUSuPeKh|ryP NVnOcpR4OjV{OEK2OVM>
SH-EP  M4D6[2Z2dmO2aX;uJGF{e2G7 NWfucVFZOjEEoN88[{9udA>? NYrpeJp1OjUEoHi= MljRbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJIVv\G:pZX7veZMhTEWSUB?= NH3W[HAzPTJ4MUm4NS=>
SCC25 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWD2ZmhoOjUEoHi= NFn2WIdKSzVyPUSzMlPDqMLzwrCxMlEzyqEQvF2= NHznfHUzPTJ{MEeyPS=>
CAL27 Mki3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV[yOOKhcA>? M3TOUmlEPTB;NUKuNeKhyrIEoEGuNFnDqM7:TR?= MW[yOVIzODd{OR?=
FaDu MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LITlI1yqCq MUnJR|UxRTJ3Lki5xsDDucLiMT6xN:Kh|ryP M{TzVlI2OjJyN{K5
SCC25 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3y0[VQ5yqCq MYjJR|UxRTJyLki2xsDDucLiMT6wO:Kh|ryP NHzVOYszPTJ{MEeyPS=>
CAL27 NGL3bZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPPOFjDqGh? NVvZWFZpUUN3ME2xPE4zPMLiwsJCpFEvOTYEoN88US=> M1;kU|I2OjJyN{K5
FaDu MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MomwOFjDqGh? NYDhc4NLUUN3ME22MlQ{yqEEsdMgNU4yO8LizszN MV2yOVIzODd{OR?=
SCC25 MmLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVi3NuKhcA>? NHjQbmdKSzVyPUiuOFHDqMLzwrCxMlEyyqEQvF2= M4jCTlI2OjJyN{K5
CAL27 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW[zcmZYPzMEoHi= NGL0SmVKSzVyPUSuNlfDqMLzwrCxMlE1yqEQvF2= MnL5NlUzOjB5Mkm=
FaDu MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPGWpU2PzMEoHi= MoLQTWM2OD13LkCyxsDDucLiMT6xOeKh|ryP M{TPWFI2OjJyN{K5
MCF-7 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrkOFjDqGkEoB?= M4ToVmROW09? MWjJR|UxRTdwMtMgxtHDqDBwONMg{txO MV2yOVIyPjN5OB?=
T-47D MonES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVn1TXdHPDkEoHlCpC=> NEC5em9FVVOR NXnWU3k5UUN3ME23MlfDqMLzwrCwMlfDqM7:TR?= M{XIelI2OjF4M{e4
MDA-MB-231 NHO1VHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17q[|Q5yqCqwrC= NH;5Tm5FVVOR NFvt[GJKSzVyPUGyMljDqMLzwrCxMlDDqM7:TR?= M33GbFI2OjF4M{e4
DU145 MmrQRZBweHSxc3nzJGF{e2G7 MkfwNVAuOTByIN88US=> M4rFU|ghcA>? MnnHSG1UVw>? NX;BSIZ[cW6mdXPld{Bk\WyuIHTlZZRpKHOrZ37p[olk[W62bImgbY4h[SC4ZYL5JIxwfyClb37j[Y51emG2aX;u MX2yOVE1QTZ6MR?=
DU145 stem-like M4XIVWFxd3C2b4Ppd{BCe3OjeR?= M3ryPFExNTFyMDFOwG0> NILyd4s5KGh? NYLqVYVxTE2VTx?= NUXyOmxrcW6mdXPld{Bk\WyuIHTlZZRpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NWjUTnRnOjVzNEm2PFE>
DU145 MUTGeY5kfGmxbjDBd5NigQ>? MYmxNE0yODBizszN NGCzTZMzKGh? NY\rcVJuTE2VTx?= MmjTbY5kemWjc3XzJJRp\SCyQ1jLNUBmgHC{ZYPzbY9vKGGwZDDk[YNz\WG|ZYOgeIhmKHCFSFuxJIV5eHKnc4Ppc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NYrBVYVTOjVzNEm2PFE>
DU145 stem-like NF:3RnpHfW6ldHnvckBCe3OjeR?= NEfTU5IyOC1zMECg{txO MYWyJIg> MWTEUXNQ MWrpcoNz\WG|ZYOgeIhmKHCFSFuxJIV5eHKnc4Ppc44h[W6mIHTlZ5Jm[XOnczD0bIUheEOKS{Gg[ZhxemW|c3nvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M2DhT|I2OTR7Nkix
UW228-3 MnTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHS5TZYxNjBzLUOwNEDPxE1? M1TCOVQ5KGh? NELFbYdFVVOR MliwTWM2OD1yLkm5xsDPxE1? Mn3mNlUyOTlzOEW=
NSCs M{HLSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV:wMlAyNTNyMDFOwG0> MoWyOFghcA>? MW\EUXNQ NXewNo8{UUN3ME2wMlMuO8LizszN M{TEPVI2OTF7MUi1
MKL-1  MkfESpVv[3Srb36gRZN{[Xl? NWfzUVloOTBvMUCwNEBvVQ>? NHvpRZM1KGR? MYHpcoR2[2W|IITo[UBqdmS3Y4Tpc44hd2ZiTVjDMWkh\XiycnXzd4lwdg>? MnH0NlUyOTZ5NUS=
MCF7 EV NFW1RlVHfW6ldHnvckBCe3OjeR?= NV3TZmlSOTBvMUCwJO69VQ>? MWmy5qCKcA>? MnjlbY5lfWOnczDwdo9lfWO2aX;uJI9nyqEQs1iyRXg> M3f5OlI2ODh6MkCz
MCF 7BMI1 M3nIZ2Z2dmO2aX;uJGF{e2G7 MnfBNVAuOTByIN88US=> MljDNwKBkWh? MUXpcoR2[2W|IIDyc4R2[3Srb36gc4bDqM7|SELBXC=> MlHxNlUxQDh{MEO=
MCF7 EV NV;YNFE5TnWwY4Tpc44hSXO|YYm= M3HlT|ExNTFyMDFOwG0> MWGy5qCKcA>? NF\nfZJGXE:SIHnu[JVk\XNiQWTNJIFkfGm4YYTpc44> M2XYS|I2ODh6MkCz
MCF7 BMI1 MnHPSpVv[3Srb36gRZN{[Xl? NIjBW2cyOC1zMECg{txO MkP6NwKBkWh? NEC1U25GXE:SIHnu[JVk\XNiQWTNJIFkfGm4YYTpc44> NVGwXlU4OjVyOEiyNFM>
HepG2 M3i1NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1P2NGROW00EoB?= Ml7QTWM2OD1|MD6xOuKhyrIEoECuOVDDqM7:TR?= NVn0bG9POjVyN{izNVE>
MOLT-3 NYHVS2liT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HTc2ROW00EoB?= NVfGUm9CUUN3ME2wMlA2OcLiwsJCpFAvODB{wrFOwG0> Mm[5NlUxPzh|MUG=
HT1080 NXqy[pNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nheFEuOTByIN88US=> MmH4OE8zPC92ODDo NED1UnpFVVORwrC= NV\UTGg{cW6mdXPld{Bk\WyuIHTlZZRpKHOrZ37p[olk[W62bImgbY4h[SC4ZYL5JIxwfyClb37j[Y51emG2aX;u Ml23NlUxPzhyNkS=
HT1080 NH[4ZWxHfW6ldHnvckBCe3OjeR?= NHPzXnUxNjByMEGtNVAxKM7:TR?= NFXK[I8yNTJ2IHi= MXjEUXNQyqB? MlHnbY5lfWOnczDwMZA2Oyi|ZYKxOUkhcW5iYn;0bEB1cW2nLTDhcoQh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgcYFvdmW{ M4fK[|I2ODd6ME[0
HT1080 NWezXFltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHHNYwxNjByMEGtNVAxKM7:TR?= M1TCdlI1KGh? MXHEUXNQyqB? NITxWJFk[XW|ZYOgZY4hcW6lcnXhd4UhcW5idHjlJI52dWKncjDv[kBk\WyuczDpckBIOi:PLDD3bIlt\SCmZXPy[YF{cW6pIGOgZY5lKEdzIIDoZZNmKGOnbHzz M1vIU|I2ODd6ME[0
HD-MY-Z MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXqcI5rOjRxNEivO|IhcA>? MlLmTWM2OO,:nkGwNEDPxE1? MXGyOVA1QDJ|Nh?=
DOHH-2 M{T1VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV[yOEBp MkXZTWM2OO,:nkGwNEDPxE1? MX:yOVA1QDJ|Nh?=
DOHH-2 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTWOFghcA>? MWLJR|UxRTF7LkpCpO69VQ>? M3K0OlI2ODR6MkO2
DOHH-2 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYi3NkBp NIftTG9KSzVyPUZCpO69VQ>? MWGyOVA1QDJ|Nh?=
REH NHW1eW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PlO|I1KGh? MUnJR|UxRTBwMEK3xsDPxE1? NYDhUJNEOjVyNEiyN|Y>
REH MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLLOFghcA>? Ml3nTWM2OD1yLkCxOOKh|ryP NYTFRploOjVyNEiyN|Y>
REH MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXGeHRiPzJiaB?= M2LtcWlEPTB;MD6wNVXDqM7:TR?= NEG2W5AzPTB2OEKzOi=>
HH MoHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWOyOEBp M3nQZmlEPTB;MUC0MlfDqM7:TR?= MlvCNlUxPDh{M{[=
HH M1H2Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHtOFghcA>? NXL6cYRWUUN3ME20PE43yqEQvF2= MkLWNlUxPDh{M{[=
HH NFTUZVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHYO|IhcA>? NIO5dpFKSzVyPUG0MlfDqM7:TR?= NYS3TIlOOjVyNEiyN|Y>
HuT-78 M3jSZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILwRVYzPCCq MXTJR|UxRTlwM9Mg{txO NH7JeHozPTB2OEKzOi=>
HuT-78 NFHiZoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUO0PEBp NHvtTFBKSzVyPUSuN:Kh|ryP MnmwNlUxPDh{M{[=
HuT-78 M2TsZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXO3NkBp Mkj1TWM2OD12LkNCpO69VQ>? M4PoZlI2ODR6MkO2
OPM-2 M{Pzemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\nNlQhcA>? MW\JR|UxRTJ2LkJCpO69VQ>? MYCyOVA1QDJ|Nh?=
OPM-2 NETVeXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGX5bXY1QCCq MWrJR|UxRTUEoN88US=> NFXZNpkzPTB2OEKzOi=>
OPM-2 NYjk[nh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfGUI04OiCq NFPEfoFKSzVyPUGuN:Kh|ryP NFL1[owzPTB2OEKzOi=>
RPMI-8226 M1vVVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2[5Z|I1KGh? MX\JR|UxRTFyNj62xsDPxE1? NGXYeXQzPTB2OEKzOi=>
RPMI-8226 NEnHN|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYX3TYZzPDhiaB?= NV7O[lNnUUN3ME25NU4yyqEQvF2= MXKyOVA1QDJ|Nh?=
RPMI-8226 Mme5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnSzO|IhcA>? MU\JR|UxRTF2LkpCpO69VQ>? NVPqbHBwOjVyNEiyN|Y>
U-266 NWnXdFQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVmyOEBp NV7WSlhLUUN3ME24Ok4zyqEQvF2= M4XlZlI2ODR6MkO2
U-266 NUPhcHM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7ROFghcA>? MUTJR|UxRTZ6LkVCpO69VQ>? MVWyOVA1QDJ|Nh?=
U-266 NE\SXnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWS3NkBp NXzTc3psUUN3ME2yO{41yqEQvF2= MXWyOVA1QDJ|Nh?=
Kelly NFv1cm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3KPYExNTFyIN88US=> MVq3NuKhcA>? NUjEPIt4UUN3ME2xMlUyQMLizszN MU[yOVAxQDlyMB?=
SH-SY5Y  MkXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWCwMVExKM7:TR?= M2PpOFczyqCq Ml3jTWM2OD1yLke1OOKh|ryPwrC= Ml7uNlUxODh7MEC=
SK-N-AS MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfwV|IxNTFyIN88US=> NIm5TII4OsLiaB?= NHrXXHJKSzVyPUGuO|EzyqEQvF5CpC=> NUnkVYhoOjVyMEi5NFA>
SK-N-DZ NWjzWmZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2m4O|AuOTBizszN MVe3NuKhcA>? MYLJR|UxRTVwNEi1xsDPxE1? MYWyOVAxQDlyMB?=
HepG2 M2q0[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYT0S3d2PDkEoHi= NHXxU2JFVVORwrC= NF7yW2xKSzVyPUGzMlY2yqEEsdMgNE46OsLizszN M1LCZ|I1QTl4MUO2
A549 M4m4PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXKOFjDqGh? NYXRO|NvTE2VT9Mg NULTcHFvUUN3ME2yOFEvQcLiwsJCpFMyNjJ|wrFOwG0> M4PjNFI1QTl4MUO2
MCF7 NEnM[4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPDe3k1QMLiaB?= MojESG1UV8Li NX3BNnZoUUN3ME24NU4xQcLiwsJCpFE1NjJzwrFOwG0> M3zrWFI1QTl4MUO2
HL-60  M2\FNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUC3NuKhcA>? NHvsWZZKSzVyPUCuNVLjiIYQvF2= MlfrNlQ6QTNyMUS=
HL-60[R] NHr6S49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TwTVczyqCq MonGTWM2OD1|LkGy5qCG|ryP NEXlSmczPDl7M{CxOC=>
MIAPACA M32xWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofZS2k2OD1zLkOgxtEhOC5yMzFOwG0> NXvKWWZPOjR7NUO4NlE>
MCF-7 NGDZXohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPmOFJIUTVyPUCuNlUhyrFiMD6xJO69VQ>? NHPvRWMzPDl3M{iyNS=>
HeLa MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvOelhIUTVyPUCuOlQhyrFiMD60JO69VQ>? MXOyOFk2Ozh{MR?=
MO59K  NU\qfWlDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYW3JIQ> NHfuR5VKSzVyPUCuNVfjiIYQvF2= NFzLW2ozPDl3M{W2NS=>
MO59J NES4eopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXm3JIQ> NF;sT5hKSzVyPUCuNgKBjc7:TR?= NXPnXnd3OjR7NUO1OlE>
ME 180 NELvOFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;6R|lUPDkEoHlCpC=> MUfJR|UxRThwOdMgxtHDqDBwM,MAie69VQ>? MX6yOFk2OzB{Nx?=
MCF-7 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUO0POKhcMLi M{HtfWlEPTB;MkOuPUDDuSByLkRihKXPxE1? Mkj1NlQ6PTNyMke=
HeLa MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHEOFjDqGkEoB?= MVrJR|UxRTRwN{GgxtEhOS524pEF{txO MkXUNlQ6PTNyMke=
MDA-MB-453 M3W0[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFm4dZg1QMLiaNMg M4nQZ2lEPTB;MUKuOUDDuSByLki15qCG|ryP Mon4NlQ6PTNyMke=
MDA-MB-231 Mn7wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXi0POKhcMLi MoXFTWM2OD1{ND6yNkDDuSB{Lkm05qCG|ryP Ml;2NlQ6PTNyMke=
PC-3 NYDQXVBvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\yOFjDqGkEoB?= M2nxb2lEPTB;MUSuOEDDuSB|LkKz5qCG|ryP M{jkelI1QTV|MEK3
HT-29 NWnKb4V3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXu0POKhcMLi NFLLN2VKSzVyPUKxMlQ2KMLzIEOuPFfjiIYQvF2= MVWyOFk2OzB{Nx?=
BGC-823 NYf4eoVvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYK0POKhcMLi Mn\aTWM2OD12Mz63OEDDuSB3LkGz5qCG|ryP MV6yOFc6Ozh5Nx?=
HeLa MmLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTXOFjDqGkEoB?= M1;iXmlEPTB;MkC5MlkxKMLzIEGzMlQzKOLChd88US=> NGmxfWkzPDd7M{i3Oy=>
A549 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXW0POKhcMLi NIDqNm9KSzVyPUGzPU42PCEEsTC3MlA26oDHzszN Ml6xNlQ4QTN6N{e=
HK-2 NULrcFhxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUS0POKhcMLi NUfMcHVOUUN3ME25MlE4KMLzIEGuOVjjiIYQvF2= NVnsNGdZOjR5OUO4O|c>

... Click to View More Cell Line Experimental Data

体内研究 Etoposide 作用于Lewis 肺癌,诱导肿瘤免疫。Etoposide按50 mg/kg剂量单独腹腔注射给药注射了Lewis肺癌细胞 (3LL)的C57B1/6小鼠,诱导60%存活。[4]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[5]
+ 展开

Topoisomerase II 活性测定:

制备核提取物,进行核分离。在Topoisomerase II去连环过程中获得去连环百分数而计算Topoisomerase II的活性。氚标记的kinoplast DNA (KDNA 0.22 μg)作为底物。Etoposide 与 Topoisomerase II在37°C 下温育30分钟,然后加入1%十二烷基硫酸钠(SDS)和蛋白酶K(100 μg/mL)终止。通过Etoposide获得去连环百分数和 Topoisomerase II 抑制情况。
细胞实验:[5]
+ 展开
  • Cell lines: 人类胶质瘤细胞系CL5
  • Concentrations: 80 μg/mL
  • Incubation Time: 1 小时
  • Method: Etoposide处理后,使用含有0.03%胰蛋白酶和0.27 mM乙二胺四乙酸(EDTA)的磷酸盐缓冲液(PBS)将细胞从培养皿中移去,然后在培养皿中稀释到适当数目,获得20到200个菌落。12天后,使用甲醇-乙酸固定培养基,使用结晶紫进行染色,并计数超过50个细胞的菌落。
    (Only for Reference)
动物实验:[2]
+ 展开
  • Animal Models: 携带血管肉瘤移植瘤ISOS-1 的小鼠
  • Formulation: 生理盐水
  • Dosages: 10 mg/kg
  • Administration: 从实验第7天开始,每天腹腔注射,持续5天
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 100 mg/mL (169.9 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+30% PEG 300+H2O
15mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 588.56
化学式

C29H32O13

CAS号 33419-42-0
稳定性 powder
in solvent
别名 VP-16, VP-16213

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03349346 Recruiting Diffuse Large B-Cell Lymphoma|Mediastinal B-cell Lymphoma Gilead Sciences June 2019 Phase 1
NCT03669783 Not yet recruiting Childhood Renal Tumor Assistance Publique Hopitaux De Marseille January 1 2019 Phase 3
NCT03742115 Not yet recruiting Hemophagocytic Lymphohistiocytosis Beijing Friendship Hospital December 1 2018 Phase 3
NCT03711305 Not yet recruiting Extensive-stage Small Cell Lung Cancer Jiangsu HengRui Medicine Co. Ltd. December 2018 Phase 3
NCT03579927 Not yet recruiting CD19 Positive|Mantle Cell Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Follicular Lymphoma M.D. Anderson Cancer Center|National Cancer Institute (NCI) December 2018 Phase 1|Phase 2
NCT03531281 Not yet recruiting Hematopoietic and Lymphoid Cell Neoplasm|Hematopoietic Cell Transplantation Recipient City of Hope Medical Center|National Cancer Institute (NCI) December 30 2018 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    Regarding the Etoposide S1225, do you have any data of the inhibition sepcificity of this product? It will inhibit other enzymes other than TOP2A?

  • 回答:

    According to the available published data, the inhibition of Etoposide is specific to TOP2A. But there're also two papers showing that Etoposide could inhibit the p34cdc2 Kinase Activity: 1. http://cancerres.aacrjournals.org/content/52/7/1817.short ; 2. http://cancerres.aacrjournals.org/content/50/12/3761.short.

Topoisomerase Signaling Pathway Map

相关Topoisomerase产品

Tags: 购买Etoposide | Etoposide供应商 | 采购Etoposide | Etoposide价格 | Etoposide生产 | 订购Etoposide | Etoposide代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID